Greenwich LifeSciences (Nasdaq: GLSI) is a public biopharmaceutical company located in Houston, TX that is developing GP2, a novel peptide immunotherapy, planning to commence a Phase III trial. In a completed Phase IIb study, no recurrences have been observed in the Her2/neu 3+ adjuvant setting after median 5 years follow-up, if the patient received the 6 primary intradermal injections over the first 6 months. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including 75% of breast cancers.
Ticker:
GLSI
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Oncology
Lead Product in Development:
GP2
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
